OptimizeRx (OPRX): Small-Cap AI Health Stock Quietly Repricing Higher
OptimizeRx (OPRX), a small-cap digital health company, is experiencing a quiet rebound driven by improving revenue trends, narrowing losses, and increased investor interest in AI-enabled healthcare. The company's strategic positioning within EHR and e-prescribing workflows for pharma messaging and data analytics, combined with a recovering small-cap risk appetite, is attracting attention despite inherent volatility. Investors are weighing its potential as a growth play in digital health against risks like client concentration and execution on AI products.
OptimizeRx (OPRX): Small-Cap AI Health Stock Quietly Repricing Higher
OptimizeRx (OPRX), a small-cap digital health company, is experiencing a rebound due to improved revenue trends, narrowing losses, and increased investor interest in AI-enabled healthcare. The company's focus on profitability, AI exposure through its digital pharma engagement platform, and recovery in small-cap risk appetite are driving this rerating. Investors are evaluating whether this is a temporary bounce or the start of a sustained growth period, given its niche competitive positioning and the evolving US healthcare digitalization landscape.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
OptimizeRx will host a conference call on March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The company will issue a press release with the financial results prior to the call. A replay of the call will be available for 12 months on the OptimizeRx website.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $21.00. The company recently reported strong quarterly earnings, beating EPS and revenue estimates, but analysts still project a negative EPS for the current fiscal year. Institutional investors hold a significant portion of the stock, which has seen some modifications in holdings by various firms.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial
OptimizeRx Corporation (Nasdaq: OPRX) has announced a conference call to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call is scheduled for March 5, 2026, at 4:30 p.m. Eastern Time. Financial results will be released via press release prior to the call, which will include a Q&A session with OptimizeRx management.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial
OptimizeRx will hold a conference call on March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter period ended December 31, 2025. The company specializes in healthcare technology solutions, utilizing AI-driven tools to connect life sciences brands with healthcare professionals and patients. A replay of the call will be available for 12 months on the investor relations section of their website.
Strength Seen in OptimizeRx (OPRX): Can Its 7.5% Jump Turn into More Strength?
OptimizeRx (OPRX) shares jumped 7.5% after the last trading session, driven by optimism regarding its operational execution in the digital pharma market, strong contracted revenue growth, and effective cross-selling strategies. The company raised its 2025 revenue guidance to $105-$109 million, but its reliance on the pharma market makes it susceptible to sector spending cycles. Upcoming quarterly earnings are projected at $0.23 per share, a 23.3% year-over-year decrease, with revenues expected to be down 2.3% to $31.58 million.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
OptimizeRx Corporation will host a conference call on Thursday, March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The company specializes in healthcare technology solutions, utilizing AI-driven tools to connect life sciences companies with healthcare professionals and patients. Financial results will be released via press release prior to the call, which will also include a question-and-answer session.
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a "Moderate Buy" consensus rating from brokerages, with an average one-year price target of $21.00. Institutional ownership is high at 76.47%, with several firms increasing their stakes, indicating strong investor confidence. The company recently reported better-than-expected earnings of $0.20 EPS against an anticipated $0.03 and revenues of $26.07 million, exceeding analyst estimates.
The 13% return this week takes OptimizeRx's (NASDAQ:OPRX) shareholders one-year gains to 156%
OptimizeRx Corporation (NASDAQ:OPRX) shareholders have seen a 156% gain over the past year, despite a 24% dip in the last quarter. The company reported a 24% revenue increase, which, while respectable, was outshone by the significant share price surge. Insiders have also been active in buying shares, indicating confidence in the company's future.
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades
OptimizeRx (OPRX) is expanding its point-of-care network through four new agreements, including an exclusive deal with an e-prescribing platform and partnerships covering the point-of-discharge phase. These expansions are expected to increase unique National Provider Identifier reach by 37%, strengthening OptimizeRx's market position and improving revenue predictability. Analysts David Grossman of Stifel Nicolaus and Eric Martinuzzi of Lake Street have reaffirmed Buy ratings on OPRX with price targets of $21 and $24, respectively.
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades
OptimizeRx Corp (NASDAQ: OPRX) is a digital health company that saw significant clinical network expansion, including an exclusive e-prescribing platform deal and new point-of-discharge partnerships. These strategic moves are expected to increase its unique National Provider Identifier reach by 37% and strengthen its market position. The company has also received reaffirmed Buy ratings and price targets from Stifel Nicolaus and Lake Street analysts.
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
OptimizeRx and Experian have announced a collaboration to enhance privacy-safe identity resolution in healthcare marketing. This partnership aims to provide life science marketers with a more accurate and transparent view of direct-to-consumer (DTC) campaign engagement and effectiveness by integrating OptimizeRx's Micro-Neighborhood® audiences with Experian's identity graph. The collaboration seeks to address fragmentation in DTC marketing, reduce audience loss during media onboarding, and improve the measurability of campaigns.
New data tie-up aims to make consumer health ads more precise and private
OptimizeRx (OPRX) announced a data collaboration with Experian on January 7, 2026, to enhance privacy-safe identity resolution in healthcare marketing. This partnership integrates OptimizeRx's Micro-Neighborhood® audiences with Experian's identity graph, aiming to improve audience activation and measurement in direct-to-consumer (DTC) healthcare campaigns. The collaboration focuses on reducing audience loss during media onboarding and increasing the accuracy of audience quality projections, thereby providing life science brands with a more transparent view of campaign effectiveness.
OptimizeRx CFO sells $18,751 in shares
Edward Stelmakh, Chief Finance & Strategy Officer at OptimizeRx Corp (NASDAQ:OPRX), sold 1,388 shares of common stock for $18,751 and exercised options for 5,237 shares on December 19, 2025. Following these transactions, Stelmakh directly owns 126,830 shares. OptimizeRx also reported strong Q3 2025 financial results, with EPS of $0.20 and revenue of $26.1 million, exceeding analyst expectations.
OptimizeRx (NASDAQ:OPRX) Insider Sells $18,751.88 in Stock
OptimizeRx (NASDAQ:OPRX) insider Edward Stelmakh sold 1,388 shares of the company's stock on December 19th for a total of $18,751.88, reducing his position by 1.08%. This transaction leaves him with 126,830 shares valued at approximately $1,713,473.30. The sale follows OptimizeRx exceeding quarterly earnings expectations, reporting an EPS of $0.20 against an anticipated $0.03 and revenues of $26.07 million.
OptimizeRx CFO sells $18,751 in shares
OptimizeRx CFO Edward Stelmakh sold 1,388 shares of the company's common stock for $18,751 on December 19, 2025. On the same day, he exercised options to acquire 5,237 shares by converting restricted stock units at a price of $0, bringing his total direct ownership to 126,830 shares. This transaction follows OptimizeRx's strong Q3 2025 financial performance, where EPS significantly beat forecasts and revenue exceeded expectations.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $16.88. The company recently reported a quarterly EPS of $0.20 and revenue of $26.07 million, both exceeding expectations, although analysts still forecast a -0.33 EPS for the current year. Insider trading activity includes the CEO selling 1,620 shares, while institutional investors collectively own 76.47% of the company's stock.
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
OptimizeRx Corp. (Nasdaq: OPRX) has announced four new partner agreements to expand its in-workflow point-of-care (POC) network, increasing its National Provider Identifier (NPI) reach by 37%. These agreements include an exclusive deal with a major e-prescribing platform, a new partnership extending into the point-of-discharge setting, and multi-year renewals with existing high-performing electronic health record and eRx partners, securing exclusive access to premium inventory. The company aims to position itself for sustained, profitable growth by enabling clients to reach a larger audience of relevant healthcare providers.
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
OptimizeRx Corp. announced four new partner agreements to expand its in-workflow point-of-care (POC) network, increasing its unique National Provider Identifier (NPI) reach by 37%. These agreements include an exclusive multi-year deal with a high-demand e-prescribing platform, a new partnership extending into point-of-discharge settings, and multi-year renewals with two top-performing EHR and eRx partners. The expansion strengthens OptimizeRx’s strategic footprint and competitive position in the POC marketing landscape, aiming for sustained, profitable growth and enhanced client value.
New partnerships plug drug makers into more doctors’ EHR workflows
OptimizeRx (Nasdaq: OPRX) announced four new partner agreements that expand its point-of-care network, including an exclusive multi-year e-prescribing agreement and a new point-of-discharge partnership. These deals increase OptimizeRx’s unique National Provider Identifier (NPI) reach by 37%, aiming to deepen workflow integration for life sciences companies. The expansion strengthens OptimizeRx's position in the POC marketing landscape, emphasizing sustained, profitable growth and measurable results for clients.
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
OptimizeRx announced four new strategic partnerships and renewals that significantly expand its in-workflow point-of-care (POC) network, increasing its unique National Provider Identifier (NPI) reach by 37%. These agreements include exclusive access to an e-prescribing platform and strengthen relationships with top-performing EHR and eRx partners, positioning OptimizeRx for continued growth in the healthcare technology sector. The company aims to enhance the value delivered to clients by enabling them to reach a larger audience of relevant healthcare professionals, driving brand awareness and conversion.
Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to "Strong-Buy"
Wall Street Zen has upgraded OptimizeRx (NASDAQ:OPRX) from a "buy" to a "strong-buy" rating, leading to a consensus "Moderate Buy" with an average price target of $16.88. This upgrade follows OptimizeRx beating Q3 expectations with $0.20 EPS and $26.07M in revenue. Despite a recent stock dip and insider selling, institutional investors hold a significant stake, with several funds increasing their positions.
Looking at the Narrative for OptimizeRx After Guidance Boost and Recurring Revenue Shift
OptimizeRx (OPRX) is under analyst scrutiny following updated guidance for 2025 and 2026, which forecasts sustained double-digit revenue growth and improved visibility. Analysts have reaffirmed a fair value estimate of around $24.33 per share, despite a slightly higher discount rate reflecting increased perceived risk. The shift towards recurring DAAP (Digital Engagement & Activation Platform) revenues is seen as a positive structural change supporting a premium valuation.
OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $16.88. The company recently exceeded earnings expectations, reporting $0.20 EPS against a $0.03 consensus, and saw its stock jump 7.4%. Despite a negative P/E ratio, institutional investors have increased their holdings, while company insiders, including the CEO, have sold shares.
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
OptimizeRx Corporation has experienced a 33% share price drop, though its stock is still up 200% over the past year. The company's price-to-sales (P/S) ratio of 2.5x is similar to the industry median, but its projected revenue growth of 8.0% is lower than the broader industry's 12% forecast. This discrepancy suggests that investors might be overpaying for the stock given its subdued growth outlook, potentially leading to future disappointment.
OptimizeRx Delivers Big Earnings Beat And Raises Outlook Again
OptimizeRx (OPRX) exceeded third-quarter expectations, with revenue up 22% to $26.1 million and robust earnings of $5.1 million in adjusted EBITDA and $3.9 million in net income. The company raised its revenue guidance for 2025 ($105–109 million) and 2026 ($118–124 million), driven by operational execution and advances in patient identification technology. Analysts maintain a positive outlook with an average 'buy' rating and a 12-month median price target of $20.
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2025 Earnings Call Transcript
OptimizeRx Corporation reported a strong Q3 2025, with revenues increasing 22% year-over-year to $26.1 million and adjusted EBITDA at $5.1 million. The company raised its full-year 2025 guidance and provided initial 2026 guidance, expecting continued strong growth driven by its omnichannel technology platform and data-driven solutions like DAAP and micro neighborhood targeting. OptimizeRx is also accelerating debt payments and seeing positive RFP trends, positioning it for sustained profitability and market share expansion in the digital pharma ecosystem.
OptimizeRx Corp. (OPRX) Tops Q3 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) exceeded Q3 earnings and revenue estimates, reporting $0.2 per share against an expected $0.03, and revenues of $26.07 million, beating the consensus by 11.25%. The stock has significantly outperformed the S&P 500 year-to-date, with its future performance largely dependent on management's upcoming commentary and earnings outlook. The current Zacks Rank for OPRX is #3 (Hold), indicating an expectation for the stock to perform in line with the market.
OptimizeRx Corp (NASDAQ:OPRX) Shows High-Growth Momentum with Strong Technical Breakout
OptimizeRx Corp (NASDAQ:OPRX) is exhibiting strong high-growth momentum, supported by a significant technical breakout that aligns with Mark Minervini's Trend Template. The stock demonstrates a robust technical profile, trading above key moving averages with rising trends and superior relative strength, alongside impressive fundamental growth metrics including accelerating EPS growth, consistent earnings surprises, and positive analyst revisions. This indicates the company is consolidating gains within a strong uptrend, presenting a potential opportunity for investors.
OptimizeRx Corp (NASDAQ:OPRX) Delivers Strong Q3 Beat and Raises Guidance
OptimizeRx Corp (NASDAQ:OPRX) significantly exceeded analyst expectations in Q3 2025 with robust growth in revenue and profitability, prompting management to raise its financial outlook for the full year. The company reported a 22% increase in revenue to $26.1 million and non-GAAP EPS of $0.20, far surpassing estimates. This strong performance, turnaround in GAAP net income, and positive market reaction suggest a sustainable growth trajectory for OptimizeRx.
OptimizeRx’s Big Bet On AI Health Pays Off—For Now
OptimizeRx (OPRX) has seen its stock skyrocket 423% over the past year, driven by earnings beats, debt reduction, and excitement around its AI health initiatives. Despite rapid revenue growth and an attractive valuation, the company faces significant risks including high debt, negative profitability, and integration challenges. Investors are weighing the strong growth prospects and AI differentiation against financial leverage and continued losses.
JMP Securities Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock - Defense World
JMP Securities has increased its target price for OptimizeRx (NASDAQ:OPRX) stock to $23.00, suggesting strong future appreciation. This follows similar positive ratings from other analysts and comes amidst insider stock sales and increased institutional investor interest. The company, a digital health technology provider, leverages AI for targeted marketing campaigns within the healthcare sector.
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
OptimizeRx (NASDAQ:OPRX) uses debt in its business, but its liquid assets are well-balanced with total liabilities. While the company's net debt to EBITDA ratio is low, its interest coverage suggests that debt levels are not trivial, especially given that EBIT improved to a positive US$3.6m only recently. Despite these considerations, OptimizeRx's strong free cash flow generation indicates a sensible approach to debt, aiming to boost shareholder returns.
OptimizeRx Corp. (OPRX) is a Great Momentum Stock: Should You Buy?
OptimizeRx Corp. (OPRX) has been identified as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of B. The article highlights OPRX's significant short-term and long-term price performance, outperforming its industry and the S&P 500. Positive earnings estimate revisions further contribute to its strong outlook as a potential investment.
OptimizeRx Corporation's (NASDAQ:OPRX) Shift From Loss To Profit
OptimizeRx Corporation (NASDAQ:OPRX) is showing signs of moving towards profitability, with analysts predicting a final loss in 2025 before achieving positive profits of US$2.1m in 2026. This projection implies a an average annual growth rate of 175% to reach breakeven, indicating a potentially optimistic outlook. The company has maintained a judicious capital structure, funding operations primarily through equity with low debt.
OptimizeRx and Lamar Advertising Form Strategic Partnership to Enhance OOH Advertising for Healthcare Marketing
OptimizeRx and Lamar Advertising have partnered to enhance out-of-home (OOH) advertising for healthcare and pharmaceutical brands. This collaboration integrates OptimizeRx's patented Micro-Neighborhood® Targeting (MNT) data with Lamar's extensive national advertising inventory, enabling targeted, clinically relevant OOH campaigns using granular geographic data related to disease prevalence. This allows healthcare marketers to reach specific patient populations effectively while complementing digital strategies and ensuring privacy compliance.
First Clinical Data-Driven OOH Ad Network: OptimizeRx and Lamar Transform Healthcare Advertising
OptimizeRx and Lamar Advertising have partnered to create the first clinical data-driven out-of-home (OOH) ad network, transforming healthcare advertising. This collaboration integrates OptimizeRx’s patented Micro-Neighborhood® Targeting (MNT) data with Lamar’s extensive OOH inventory, enabling precise targeting of healthcare audiences at the ZIP+4 level. This approach offers healthcare marketers a cost-effective and measurable solution for reaching clinically relevant patient populations while maintaining privacy.
OptimizeRx Corp (NASDAQ:OPRX) Combines Technical Strength with High-Growth Momentum
OptimizeRx Corp (NASDAQ:OPRX) is presented as a strong investment candidate, aligning with Mark Minervini's Trend Template for technical strength and exhibiting significant growth momentum. The article highlights OPRX's robust technical indicators, including price stability above key moving averages and superior relative strength, alongside impressive fundamental growth in earnings, revenue, and free cash flow. This combination suggests a company in a vigorous expansion phase, making it attractive for growth-focused investors despite requiring careful attention to entry timing due to recent volatility.
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
OptimizeRx Corporation has announced several leadership advancements to accelerate its strategic growth and balance sustained growth with increased profitability. Key appointments include Ed Stelmakh as Chief Financial & Strategic Officer, Theresa Greco continuing as Chief Commercial Officer, Marion Odence-Ford as Chief Legal & Administrative Officer, Doug Besch as Chief Product & Technology Officer, Brendan Merrell as Chief Operating Officer, and Andy D’Silva promoted to Chief Business Officer. These changes are intended to align talent and structure with the company's long-term strategic objectives and drive its "Rule of 40" strategy.
OptimizeRx announces leadership reorganization to drive growth strategy
OptimizeRx Corp. (NASDAQ: OPRX) announced a leadership reorganization Tuesday, designed to accelerate its "Rule of 40" strategy for growth and profitability. Key appointments include Ed Stelmakh as Chief Financial & Strategic Officer, Brendan Merrell as COO, and Andy D’Silva as Chief Business Officer, while Theresa Greco and Marion Odence-Ford also take on expanded roles. The company's recent Q2 2025 financial results showed significant revenue growth and EPS outperformance, leading to an increased price target from JMP Securities.
OptimizeRx’s SWOT analysis: digital health firm’s stock faces scaling hurdles
OptimizeRx (NASDAQ: OPRX), a digital health messaging platform, has shown significant growth with a 237.45% return year-to-date and strong Q2 2025 financial results, including revenue growth of 55%. Despite this performance, the company faces challenges in scaling beyond $100 million in annual revenue and slower-than-expected growth in its direct-to-consumer (DTC) segment after the Medicx acquisition. Strategic alternatives, including a potential sale and a shift towards subscription-based revenues, are being explored to unlock shareholder value and ensure long-term financial stability.
Earnings call transcript: OptimizeRx Q2 2025 sees EPS surprise, stock jumps
OptimizeRx Corp (NASDAQ: OPRX) significantly surpassed analyst expectations in Q2 2025 with an EPS of $0.24 against a forecast of $0.02 and revenue of $29.2 million, beating projections by 31.18%. This strong performance led to a 23.05% jump in stock price during premarket trading, and the company has raised its full-year revenue guidance to between $104 million and $108 million. The company reported a net income of $1.5 million, reversing a $4 million loss from the prior year, and demonstrated operational efficiency with stable operating expenses despite substantial revenue growth.
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
OptimizeRx Corporation has appointed Stephen Silvestro as its new Chief Executive Officer, effective March 10, 2025. Silvestro, who has been with OptimizeRx since 2019 and previously served as President and interim CEO, brings over 20 years of experience in health technology and services. The appointment follows a rigorous search by the company's independent Directors, who believe Silvestro is the right leader to drive the company's next phase of profitable revenue growth and shareholder value creation.
OptimizeRx Empowers Patients and Providers with Telemedicine Tools Tailored for Women’s Health
OptimizeRx Corp. (Nasdaq: OPRX) announced that True™ Women’s Health launched a new health app powered by RMDY digital health tools, enabling virtual care and personalized women's health programs nationwide, particularly during the COVID-19 pandemic. The app supports patients in managing menopause symptoms and other health conditions through educational videos, trackers, and telehealth consults. This collaboration highlights OptimizeRx's commitment to improving patient engagement and outcomes through technology-driven healthcare solutions.
optimizeRX buys digital health co RMDY
optimizeRX (Nasdaq: OPRX) has acquired digital health company RMDY for up to $46 million. TASE-listed companies ICB Biotechnology Investments and Merchavia Holdings and Investments, which each held a 6% stake in RMDY, are expected to see significant returns on their investment. RMDY, founded by Amir Kishon, developed a digital therapeutics platform and operates in the US.
OptimizeRx Announces New Partnership with Health IT Pioneer lllumiCare
OptimizeRx announced a new partnership with IllumiCare to integrate its RxSavings App into IllumiCare's Smart Ribbon® platform. This collaboration aims to improve communication between pharma, providers, and patients by offering drug savings opportunities directly at the point-of-care, addressing rising drug costs and enhancing patient adherence. The RxSavings App is scheduled to launch in Q2 2019.
OptimizeRx Acquires CareSpeak Communications to Expand Pharma Mobile Messaging
OptimizeRx Corp., a digital health messaging provider for the pharmaceutical industry, has acquired CareSpeak Communications, a company specializing in interactive health messaging for improved medication adherence and care coordination. This acquisition allows OptimizeRx to expand its communication reach directly to patients, supporting greater medication adherence, engagement, and improved health outcomes. The deal aims to address the critical need for direct communication between pharma and patients, utilizing CareSpeak's technology through OptimizeRx's nationwide network.
OptimizeRx Partners with EvidenceCare to Deliver Real-time Medication Messaging
OptimizeRx Corp., a digital health messaging provider for the pharmaceutical industry, has partnered with EvidenceCare, a clinical decision support tool provider. This partnership will allow EvidenceCare to deliver OptimizeRx's digital health messaging, including financial, clinical, and brand messages for pharmaceutical companies, to healthcare providers at the point-of-care. The integration aims to enhance the care process by providing valuable information to clinicians.
